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Amphotericin B is the most potent antimycotic known to date. However due to its large col-
lateral toxicity, its use, although long standing, had been limited. Many attempts have been
made to produce derivatives with reduced collateral damage. The molecular mechanism of
polyene has also been closely studied for this purpose and understanding it would contrib-
ute to the development of safe derivatives. Our study examined polyene action, including
chemical synthesis, electrophysiology, pharmacology, toxicology and molecular dynamics.
The results were used to support a novel Amphotericin B derivative with increased selectiv-
ity: L-histidine methyl ester of Amphotericin B. We found that this derivative has the same
form of action as Amphotericin B, i.e. pore formation in the cell membrane. Its reduced
dimerization in solution, when compared to Amphotericin B, is at least partially responsible
for its increased selectivity. Here we also present the results of preclinical tests, which
show that the derivative is just as potent as Amphotericin B and has increased safety.
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Introduction
Polyene antibiotics have been used for over six decades, mainly as therapeutics for antimyco-
tic purposes, as well as in the treatment of other ailments produced by a number of protozoa
and viruses [1]. The proposedmechanism of action is the formation of pores in the cell mem-
brane, even if other mechanisms, such as inhibition of the fungal proton ATPase, lipid perox-
idation and apoptotic-like responses, have also been described [2,3]. In spite of it being a
long-standing proposal, there is still ongoing controversy regarding how polyenes work to
produce these pores. The transmembrane ion conductance produced is clear, as shown by
electrophysiological experiments [4,5]. This is also true for other simple molecules, as natural
peptides [6] that produce this effect. The standard model, proposed a long time ago [4,5],
states that a barrel of polyene molecules, in particular Amphotericin B (AmB)—the most typ-
ical of these antibiotics—, forms a hydrophilic pore with the hydrophobic chain of the poly-
ene embedded in the lipid membrane. This 'standard' model has been extended to propose
that the barrel structure is stabilized by interactions between adjacent monomers, with the
membrane phospholipids and sterols contained in the grooves betweenAmB monomers.
The fact that polyenes present greater activity in cells containing ergosterol (fungi) than cho-
lesterol (mammalian) confers them “selectivity” and enables their therapeutic use. The stan-
dard model suggests that this is due to a better interaction of ergosterol with the polyene,
which leads to greater stability of the pores thus formed, according to said model. However,
there is ample contradictory evidence as reviewed in Récamier et al. [7] and González-
Damián et al. [8]. An alternative model, based on the presence of channels in sterol-free
membranes [9–13], has been proposed [11,13]. This discussion is focused on one mechanism
proposed for the action of polyenes: the formation of membrane pores. There are however
other mechanisms, such as oxidative cell damage (Bratjberg et al. [14] and Sokol-Anderson
[15]), destabilization of the membrane (de Kruijff and Demel [16] and Mouri et al. [17]) and
the recently developed sterol extraction by clusters of the polyene: the sponge model (Palacios
et al. [18)] and Gray et al. [19]).
The sponge model has also lead to the design of a novel derivative presenting greater selec-
tivity [20]. Two recent studies, one using chemical synthesis [18] and another one using
molecular dynamics [21], support this model. The first one has suggested that the mycosa-
mine ring interacts with the sterols in a differentiatedmanner and thus produces selectivity.
The lack of activity when mycosamine was deleted, a previously known fact [22], is taken as
evidence for this. In the second study, the binding free energy betweenAmB and both sterols
in a 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) membrane shows a greater affin-
ity for ergosterol over cholesterol, a requirement for the sponge model. This has been sup-
ported by a recent work using neutron reflectometry, which observes the deposition of large
aggregations of AmB, but in supported bilayers and after a very large amount of AmB vs. lipid
concentration [23]. Both works have contributed to the understanding of the mechanism of
action, although they disregard strong evidence; e.g. in absence of sterols, the polyene chan-
nels have the same characteristics as those observedby single channel analysis in a sterol con-
taining membrane [7,8,11,13]. Also, recent results show that the activity of Nystatine, a close
analog of AmB, has a high correlation with the phase diagram of POPC/sterol mixtures [8].
Given the same amount of sterol, different activities are observed for the distinct liquid phases.
Moreover, there are conditions in the phase diagramwhere reversed selectivity is observed,
i.e., a greater activity in cholesterol over ergosterol-containing membranes. The same phe-
nomenon was observedwith AFMmicroscopy but only in ergosterol-containing supported
lipid bilayers [24]. Several models have been recently revised by Kamiski et al. [25]. We have
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focused on the pore model because it allows for an explanation of the increment in selectivity
attained by a new derivative.
Additional interest in understanding the mode of action of polyenes lies in their importance
for therapeutic treatment. A number of commercial products have already improved on the
use of AmB by reducing its collateral toxicity, such as a lipid complex like Abelcet1, a lipo-
somal formulation like AmBisome1 and, more recently, the proposal for polymeric nanoparti-
cles and nanosuspensions [26]. There are indeed advantages in the use of these presentations,
but remnant toxicity still hinders their use, in addition to the fact that these presentations con-
siderably increase treatment costs and could reduce the efficacy of the drug [27]. Thus more
selective chemical derivatives are required, i.e., derivatives that improve the effectiveness of the
molecular function, leading to more cost-effective alternatives that could in due course be con-
sidered for special delivery systems.
This is a multidisciplinary study has furthered the understanding of AmB’s modes of action.
It considers other recent derivatives [21,28,29] that have shown reduced collateral toxicity
towards mammalian cells, and presents a new derivative with a considerable advantage in this
regard [30]. The derivative design is based on the idea that selectivity is related to membrane
structure.We have therefore considered amide substitutions in the carboxylic group in order
to force the sugar ring towards the membrane. The idea is that this moiety, which is essential
for drug activity [23], will sense the membrane structure as well as the amides themselves. This
idea could also be related to the proposed hypothesis [31] that cholesterol-containing mem-
branes require dimerization for AmB to incorporate it. Chemical derivatives were tested on
membrane patches to check their ability to produce K+ leakage and in microbiological studies
to determine their selectivity. A novel derivative with increased safety was thus obtained. This
derivative was subjected to molecular dynamics, electrophysiological, pharmacological and
spectrophotometric studies in order to understand the basis of the increased selectivity. Pre-
clinical trials were also undertaken to establish its increased safety.
Materials
All chemicals were obtained> 95% pure from commercial suppliers and used as received
unless otherwise stated. POPC dissolved in chloroform was purchased from Avanti Polar Lip-
ids (Alabaster, AL). Powdered lecithin, cholesterol, ergosterol and AmB for pharmacological
tests were purchased from Sigma-Aldrich (Toluca, Mexico), stored at -20 C (4 C for AmB)
under vacuum and used without further purification. Stock chloroform solutions for every
lipid were prepared once a week and stored at -20 C. AmB was purchased from Indofine
Chemical Company Inc. (Hillsborough, NJ). Abelcet1 suspension was purchased from Arm-
strong Laboratories (DF Mexico). Sealed vials of ergosterol dissolved in chloroform were pur-
chased from Supelco (Bellefonte, PA) and stored at 4 C in the dark. Dimethyl sulfoxide
(DMSO, synthesis grade), potassium chloride (KCl, ACS grade) and calcium chloride (CaCl2,
ACS grade) were purchased fromMerck (Naucalpan, Mexico). Dubelcco’s PBS was purchased
from Caisson Labs (North Logan, UT). All organic solvents were ACS grade and were pur-
chased from J. T. Baker (Xalostoc,Mexico). Evaporation of the solvents was done in a rotative
evaporator (B-177; Büchi Labortechnik, Flawil, Switzerland). UV spectra were obtained in a
Hitachi U-5100 Spectrophotometer. Borosilicate glass capillaries were obtained fromWorld
Precision Instruments (Sarasota, FL). High-purity nitrogen gas was supplied by Praxair (Cuer-
navaca, Mexico). Other chemicals were purchased from Sigma-Aldrich (Toluca, Mexico).
Balb-Cmice (20–23 g) were purchased fromHarlan México, S.A. de C.V. Blood samples were
obtained from the blood bank of Instituto Nacional de Cancerología,México, to avoid the risk
of transmission of infectious agents.
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Methods
Chemical Synthesis
ChemistryGeneral Procedures. A1-A7 derivatives did not show an increased fungal/
mammal selectivity and therefore no precise determination of purity was performed.However,
since they have molecular weights above 1000 atomic units and the high-resolutionmass spec-
troscopy measurements compare well with the calculated ones (Table 1), we were able to esti-
mate a degree of purity of ~ 90%. All reactions using moisture and/or air-sensitive reagents
were carried out in oven-dried glassware under nitrogen atmosphere; reactions involving
Amphotericin B were protected from light. Thin Layer Chromatography (TLC) was run on
Aldrich silica gel plates l.t. 200 μm on aluminum foil, and compounds were visualized using
both/either ninhydrin solution and UV light. 1H NMR spectra were recorded on Inova Varian
(400 and 700 MHz) instruments. Resulting data were tabulated in the following order: chemical
shift (δ), multiplicity (br, broad; s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet of dou-
blets; m, multiplet), coupling constant(s) J (Hz), number of protons and assignation. Tetra-
methylsilane was used as internal reference in CDCl3 (δH = 0). When using DMSO-d6 or D2O,
the solvent residual peak (δH = 2.50 and 4.80 ppm, respectively) was used as internal reference.
13C NMR spectra were recorded in the same instruments using the central signals of CDCl3
and DMSO-d6 (δC = 77.16 and 39.52 ppm, respectively) as reference signals. High and low res-
olution MS data were obtained on a JEOLMStation JMS-700. IR spectrumdata was obtained
on a Bruker Vector 22 FT-IR instrument.Melting points were determined in capillary tubes
and are uncorrected. The analytical data obtained for known compounds agree with those pre-
viously reported for these compounds.
Synthesis of Amphotericin B amide analogues (A1–A7). Et3N (5.0 mMol), DPPA (5.0
mMol) and the selected amine (5.0 mMol) were added to a stirred solution of Amphotericin B
(0.5 mMol) in 10 ml of DMAC [32] under nitrogen atmosphere (Fig 1). The reactionmixture
was stirred at room temperature (rt) until complete consumption of the startingmaterials
(TLC system: methanol–chloroform–water 20:10:1 v/v). The product was precipitated with
anhydrous diethyl ether, dissolved in n-BuOH and washed with water (2 x 50 ml). The solvent
was evaporated at reduced pressure. The product was precipitated and subsequently washed
with anhydrous diethyl ether (3 x 50 ml) and hexanes (1 x 50 ml).
AnalogueA1,N-benzylamideof AmB: This analogue was obtained in yield 34% and iso-
lated as a yellow solid with mp 187 C (dec). 1H (700 MHz, DMSO-d-6): δ 7.29–7.21 (m, 5 H),
Table 1. Post-purification yields, representative Infrared signals and High Resolution Mass Spectrometry obtained in the synthesis of AmB
amide analogues.
Analogue Yield (%) IR bands (cm-1) M/Z
C = O (acid) C = O (amide) Calculated Measured*
AmB - - 1711.0 - - 923.4878 924.4930
N-benzylamide of AmB (A1) 95.50 N. O. 1645.4 1012.5508 1013.6540
N-cyclohexylamide of AmB (A2) 88.90 N. O. 1640.9 1004.5821 1005.6092
N, N-diisopropylamide of AmB (A3) 93.11 N. O. 1642.8 1006.5977 1007.6423
N-(S)-α-phenylethylamide of AmB (A4) 99.00 N. O. 1631.3 1026.5664 1027.5898
N-(R)-α-phenylethylamide of AmB (A5) 98.45 N. O. 1630.1 1026.5664 1027.5785
N-(L)-tryptophanamide of AmB (A6) 65.13 N. O. 1635.4 1123.5828 1124.5276
N-(D)-tryptophanamide of AmB (A7) 93.85 N. O. 1638.2 1123.5828 1124.6073
L-histidine methyl ester of AmB (A21) 84.90 N. O. 1652.38 1075.5702 1075.5719
* Measured values are presented as [M + H]+
doi:10.1371/journal.pone.0162171.t001
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6.45–5.94 (m, 12 H), 5.83 (s, 1 H), 5.46–5.39 (m, 2 H), 5.20 (br, 1 H), 4.77–4.72 (m, 2 H), 4.45–
4.22 (m, 6 H), 4.04–3.98 (m, 3 H), 3.76–3.45 (m, 6 H), 3.22 (s, 1 H), 3.15–3.07 (m, 2 H), 2.94–
2.92 (m, 1 H), 2.28 (m, 2 H), 2.16 (m, 1 H), 2.03–1.97 (m, 2 H), 1.89–1.21 (m, 16 H, CH2, CH),
1.12–1.09 (m, 6 H, CH3), 1.02 (d, J = 5.8 Hz, 3 H, CH3), 0.90 (d, J = 6.6 Hz, 3 H). Due the low
solubility of A1 wasn’t possible to obtain 13C spectra. HRMS (FAB+): [M + H]+ calcd for
C54H80N2O16, 1013.5508; found, 1013.6540.
AnalogueA2,N-cyclohexylamideof AmB: This compound was obtained in yield 54% and
isolated as a yellow solid with mp 143 C (dec). 1H (700 MHz, DMSO-d-6): δ 6.45–5.92(m, 12
H), 5.81–5.76 (br, 1 H), 5.43–5.40 (m, 1 H), 5.20 (br, 1 H), 4.77–4.64 (m, 2 H), 4.45–4.36 (m, 2
H), 4.30 (s, 1 H), 4.22–4.18 (m, 2 H), 4.04–4.02 (m, 2 H), 3.62 (s, 1 H), 3.54–3.50 (m, 2 H),
3.19–3.15 (m, 1 H), 3.09–3.06 (m, 2 H), 3.00–2.95 (m, 1 H), 2.39 (d, J = 8 Hz, 1 H), 2.28–2.26
(m, 1 H), 2.15 (d, J = 4.7 Hz, 2 H), 1.97–1.95 (m, 1 H), 1.89–1.22 (m, 22 H), 1.17–1.05 (m, 9 H),
1.02 (d, J = 6.1 Hz, 3 H), 0.89 (d, J = 6.9 Hz, 3 H). 13C (175 MHz, DMSO-d-6): δ 171.30, 171.01,
137.20, 134.33, 134.13, 133.91, 133.63, 132.92, 132.87, 132.63, 132.31, 132.28, 131.65, 129.02,
97.51, 97.08, 77.60, 74.76, 74.25, 74.01, 73.65, 69.77, 69.56, 69.30, 68.20, 66.63, 65.75, 64.91,
57.16, 57.01, 47.82, 33.31, 32.82, 29.46, 25.66, 25.03, 24.91, 18.93, 18.33, 17.41, 12.52. HRMS
(FAB+): m/z [M + H]+ for C53H84N2O16 calcd: 1005.5821, found: 1005.6092.
AnalogueA3,N,N-diisopropylamideof AmB: This compound was obtained in yield 36%
and isolated as a yellow solid with mp 140 C (dec). 1H (700 MHz, DMSO-d-6): δ 6.45–5.92 (m,
12 H), 5.44–5.40 (m, 1 H), 5.19 (br, 1 H), 4.36–4.34 (m, 1 H), 4.31 (s, 1 H), 4.21 (m, 1 H), 4.04–
Fig 1. Synthesis of Amphotericin B amide analogues A1–A7. Reagents and conditions: (a) Selected amine, DPPA, Et3N,
DMAC, rt.
doi:10.1371/journal.pone.0162171.g001
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4.03 (m, 2 H), 3.88–3.82 (m, 1 H), 3.50 (m, 1 H), 3.10–3.06 (m, 2 H), 3.02–3.00 (m, 1 H), 2.28–
2.26 (m, 1 H), 2.15 (d, J = 4.7 Hz, 1 H), 1.88–1.21 (m, 20 H), 1.17–1.01 (m, 15 H), 0.89 (d,
J = 6.9 Hz, 3 H). 13C (175 MHz, DMSO-d-6): δ 171.35, 171.01, 137.23, 134.31, 134.15, 133.88,
133.63, 132.93, 132.65, 132.31, 131.65, 129.07, 97.51, 96.76, 77.55, 74.27, 74.01, 73.54, 73.49,
69.66, 69.57, 69.32, 68.22, 66.77, 66.63, 65.63, 65.00, 56.68, 30.04, 29.46, 23.09, 22.89, 18.93,
18.26, 17.42, 12.52.; HRMS (FAB+): m/z [M + H]+ for C53H86N2O16 calcd: 1007.5977, found:
1007.6423.
AnalogueA4,N-(S)-α-phenylethylamide of AmB: This compound was obtained in yield
37% and isolated as a yellow solid with mp 161 C (dec). 1H (700 MHz, DMSO-d-6): δ 7.38–7.21
(m, 5 H), 6.47–5.96 (m, 12 H), 5.46–5.42 (m, 1 H), 5.22 (br, 1 H), 5.00 (m, 1 H), 4.43–4.38 (m,
2 H), 4.26 (m, 2 H), 4.06 (m, 2 H), 3.74 (s, 1 H), 3.52–3.47 (m, 2 H), 3.11 (m, 2 H), 2.285 (m, 1
H), 2.16 (m, 1 H), 2.04 (m, 1 H), 1.895 (m, 1 H), 1.72–1.23 (m, 15 H), 1.19–1.08 (m, 6 H), 1.04
(d, J = 6.1 Hz, 3 H) 0.91 (d, J = 6.9, Hz, 3 H). 13C (175 MHz, DMSO-d-6): δ 172.38, 171.01,
144.52, 137.24, 134.31, 134.15, 133.85, 133.62, 132.96, 132.66, 132.31, 131.61, 129.22, 128.49,
126.91, 126.65, 97.55, 96.70, 69.67, 69.56, 69.52, 69.32, 68.23, 66.63, 66.59, 65.67, 65.12, 47.76,
29.46, 22.87, 18.98, 17.43, 12.52. HRMS (FAB+): m/z [M + H]+ for C55H82N2O16 calcd:
1027.5664, found: 1027.5898.
AnalogueA5,N-(R)-α-phenylethylamide of AmB: This compound was obtained in yield
33% and isolated as a yellow solid with mp 166 C (dec). 1H (700 MHz, DMSO-d-6): δ 7.35–7.12
(m, 5 H), 6.48–5.95 (m, 12 H), 5.49–5.40 (m, 1 H), 5.23 (br, 1 H), 5.00–4.94 (m, 1 H), 4.78–4.73
(m, 1 H), 4.36 (s, 1 H), 4.24 (m, 2 H), 4.11–3.99 (m, 2 H), 3.55–3.48 (m, 2 H), 3.24 (br, 1 H),
3.13–3.09 (m, 2 H), 2.28 (m, 1 H), 2.16 (m, 1 H), 1.89 (m, 1 H), 1.72–1.23 (m, 15), 1.13–1.10
(m, 6 H), 1.04 (d, J = 5.5 Hz, 3 H), 0.91, (d, J = 6.3 Hz, 3 H). 13C (175 MHz, DMSO-d-6): δ
172.39, 171.02, 145.13, 137.19, 134.30, 134.14, 133.73, 133.62, 132.97, 132.72, 132.66, 132.33,
131.74, 128.89, 128.85, 128.62, 128.34, 126.40, 99.12, 97.64, 74.40, 73.92, 69.66, 69.51, 69.16,
68.34, 66.59, 65.89, 64.77, 47.61, 29.49, 18.98, 18.63, 17.35, 12.56. HRMS (FAB+): m/z [M
+ H]+ for: C55H82N2O16 calcd: 1027.5664, found: 1027.5785.
AnalogueA6,N-(L)-tryptophanamide of AmB: This compound was obtained in yield
60% and isolated as a yellow solid with mp 142 C (dec). 1H (700 MHz, DMSO-d-6): δ 7.98 (br, 1
H), 7.44 (d, J = 7.7 Hz, 1 H), 7.31 (d, J = 7.9 Hz, 1 H), 7.25 (s, 1 H), 7.21 (br, 1 H), 7.05 (dd,
J = 7.9, 7 Hz, 1 H), 6.97 (dd, J = 7.7, 7 Hz, 1 H), 6.46–5.97 (m, 12 H), 5.80 (s, 1 H), 5.67 (d,
J = 5.4 Hz, 1 H), 5.44–5.40 (m, 1 H), 5.34 (d, J = 5.2 Hz, 1 H), 5.20 (m, 1 H), 4.78–4.72 (m, 1
H), 4.69 (dd, J = 7.0, 7.0 Hz, 1 H) 4.52–4.47 (m, 1 H), 4.40 (br, 1 H), 4.23 (m, 1 H), 4.05–4.00
(m, 3 H), 3.81 (br, 1 H), 3.57 (s, 3 H), 3.52 (m, 1 H), 3.26–3.19 (m, 1 H), 3.14–3.03 (m, 1 H),
2.29–2.25 (m, 1 H), 2.16 (d, J = 5.1 Hz, 1 H), 1.89–1.87 (m, 1 H), 1.71–1.21 (m, 14 H), 1.165 (d,
J = 6.0 Hz, 3 H), 1.13 (d, J = 5.6 Hz, 3 H), 1.09 (d, J = 6.3 Hz, 3 H). 13C (175 MHz, DMSO-d-6):
δ 173.10, 172.83, 171.01, 136.46, 136.41, 134.33, 134.11, 133.87, 133.62, 132.94, 132.65, 132.30,
131.67, 127.51, 124.2, 121.36, 118.81, 118.3, 111.83, 109.78, 97.57, 95.51, 77.58, 73.07, 69.53,
69.31, 69.06, 69.02, 68.31, 67.50, 66.78, 66.62, 66.46, 65.50, 65.38, 55.95, 53.36, 52.34, 29.48,
27.21, 18.92, 18.11, 17.40, 12.52. HRMS (FAB+): m/z [M + H]+ calcd for: C59H85N3O18
1124.5828, found: 1124.5276.
AnalogueA7,N-(D)-tryptophanamide of AmB: This compound was obtained in yield
68% and isolated as a yellow solid with mp 146 C (dec). 1H (700 MHz, DMSO-d-6): δ 7.98 (br, 1
H), 7.44 (d, J = 7.7 Hz, 1 H), 7.31 (d, J = 7.9 Hz, 1 H), 7.25 (s, 1 H), 7.21 (br, 1 H), 7.05 (dd,
J = 7.9, 7 Hz, 1 H), 6.97 (dd, J = 7.7, 7 Hz, 1 H), 6.46–5.97 (m, 12 H), 5.80 (s, 1 H), 5.67 (d,
J = 5.4 Hz, 1 H), 5.44–5.40 (m, 1 H), 5.34 (d, J = 5.2 Hz, 1 H), 5.20 (m, 1 H), 4.78–4.72 (m, 1
H), 4.69 (dd, J = 7.0, 7.0 Hz, 1 H) 4.52–4.47 (m, 1 H), 4.40 (br, 1 H), 4.23 (m, 1 H), 4.05–4.00
(m, 3 H), 3.81 (br, 1 H), 3.57 (s, 3 H), 3.52 (m, 1 H), 3.26–3.19 (m, 1 H), 3.14–3.03 (m, 1 H),
2.29–2.25 (m, 1 H), 2.16 (d, J = 5.1 Hz, 1 H), 1.89–1.87 (m, 1 H), 1.71–1.21 (m, 14 H), 1.16 (d,
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J = 6.0 Hz, 3 H), 1.13 (d, J = 5.6 Hz, 3 H), 1.09 (d, J = 6.3 Hz, 3 H). 13C (175 MHz, DMSO-d-6):
δ 173.10, 172.83, 171.01, 136.46, 136.41, 134.33, 134.11, 133.87, 133.62, 132.94, 132.65, 132.30,
131.67, 127.51, 124.2, 121.36, 118.81, 118.3, 111.83, 109.78, 97.57, 95.51, 77.58, 73.07, 69.53,
69.31, 69.06, 69.02, 68.31, 67.50, 66.78, 66.62, 66.46, 65.50, 65.38, 55.95, 53.36, 52.34, 29.48,
27.21, 18.92, 18.11, 17.40, 12.52. HRMS (FAB+): m/z [M + H]+ for C59H85N3O18 calcd:
1124.5828, found: 1124.6073.
Synthesis of Amphotericin B amide analogueA21. a) L-histidinemethyl ester dihy-
drochloride.SOCl2 (10 ml, 137 mMol) was slowly added to a stirred solution of L-histidine (5
g, 32.22 mMol) in 30 ml of methanol at 0 C. The reactionmixture was then heated to 60 C for
6 h (TLC system: methanol) (Fig 2). The solvent was evaporated, and the crude product recrys-
tallized frommethanol/ether [33] to obtain the L-histidinemethyl ester dihydrochloride 21
which was used without further purification (yield 99.00%): mp 195 C; 1H NMR (200 MHz
D2O) δ 8.72 (s, 1H, Im-2-H), 7.50 (s, 1H, Im-5-H), 4.55 (t, J = 7 Hz, 1H, NH2CH), 3.86 (s, 3H,
CH3), 3.51 (m, 2H, CH2).
b) Preparation of analogueA21 up to 100 mg. Et3N was added drop wise to a solution of
Amphotericin B (0.195 mMol) and L-Histidine methyl ester dihydrochloride 21 (0.409
mMol, 2.1 eq.) in DMSO until pH = 8. The resulting mixture was stirred for 15 minutes. After
this, PyBOP (0.292 mMol, 1.5 eq.) was added under nitrogen atmosphere, the flask was sealed
and stirred for 72 h at rt. (TLC system: methanol–chloroform–water 20:10:1 v/v). The prod-
uct was precipitated and washed with anhydrous diethyl ether (5 x 5 ml) and anhydrous ace-
tone (5 x 30 ml). The suspension obtained was centrifuged at 3500 rpm for 10 minutes. The
solvent was decanted and the product dried at reduced pressure to obtain a yellowish powder
corresponding to the AmB analogueA21. This compound was obtained in yield 84.9% and
Fig 2. The synthesis of the A21 analogue produced from Amphotericin B. Reagents and conditions: (a) SOCl2,
MeOH, 60˚C; (b) AmB, PyBOP, Et3N, DMSO, rt.
doi:10.1371/journal.pone.0162171.g002
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isolated as a yellow solid with mp 140–145 C (dec); 1H NMR (Fig 3) (700 MHz, pyridine) δ
8.16 (d, J = 12.1 Hz, 1 H, Im-2-H), 7.09 (s, 1 H, Im-5-H), 6.96–6.26 (m, 14 H, olefinicH), 5.89
(d, J = 6.8 Hz, 3 H), 5.54 (dd, J = 24.2, 13.8 Hz, 3 H), 5.39–5.20 (m, 4 H), 5.20–4.65 (m, 9 H),
4.49 (s, 1 H), 4.40–4.09 (m, 4H), 4.03–3.96 (m, 1H), 3.81–3.36 (m, 6H, methyl ester of L-His
H included), 3.11–2.60 (m, 6H), 2.59–2.39 (m, 3H), 2.30–1.18 (m, 26H, aliphatic H), 1.17–
0.95 (m, 2H), 0.93–0.77 (m, 1H). 13C NMR (Fig 4) (176 MHz, pyridine) δ 174.21, 173.85,
173.02, 172.21, 150.81, 150.57, 149.91, 137.66, 136.30, 136.20, 136.16, 135.60, 134.98, 134.26,
133.54, 133.26, 133.00, 124.18, 124.13, 123.57, 101.69, 98.57, 98.44, 78.84, 76.95, 75.41, 75.33,
74.98, 72.32, 70.40, 70.16, 68.68, 67.06, 66.53, 58.32, 54.56, 52.55, 47.74, 46.26, 45.62, 44.08,
43.33, 43.24, 41.42, 36.88, 32.28, 30.54, 19.38, 18.95, 18.84, 17.67, 17.64, 13.12, 9.28; HRMS
(FAB+): m/z [M + H]+ for C54H82N4O18 calcd: 1075.5702, found: 1075.5719; IR vmax
3274.23
c) Preparation of analogueA21 up to 10 g. In a 3 neck 1 L flask provided with mechanical
stirrer, thermometer, input and output of nitrogen, 10 g (10.82 mMol) of AmB and 5.24 g
(21.64 mMol), of L-Histidine methyl ester dihydrochloride in 100 ml of DMSO were loaded
in the absence of light. 6.78 ml of Et3N (48.7 mMol) was added dropwise to the resulting
slurry, which was then stirred for 15 minutes. PyBOP (11.26 g; 21.65 mMol) was added at
once under nitrogen atmosphere. The flask was sealed and stirred for 12–24 h at rt., verifying
the total consumption of AmB by HPLC analysis. Reactionmonitoring was performed on a
Waters 600 HPLC System equipped with UV 486 detector under the following parameters:
Fig 3. 1H NMR spectrum of A21 analogue.
doi:10.1371/journal.pone.0162171.g003
An Amphotericin B Derivative Equally Potent to Amphotericin B and with Increased Safety
PLOS ONE | DOI:10.1371/journal.pone.0162171 September 28, 2016 8 / 38
Column: Symmetry C18 4.6 x 75 mm, 3.5 μm, Mobile phase: CH3CN/ AcOH/Et3N 30 mMol
pH = 4 Buffer, (30:70), Injection volume: 5 μL/0.125 mg/ml, Flow: 1 ml/min and λ = 383 nm.
The DMSO solution was washed with anhydrous MTBE (6 x 100 ml) and precipitated by the
addition of anhydrous acetone (1 l). The suspension obtained was centrifuged at 3500 rpm for
10 minutes at 4 C. The solvent was decanted, the product washed again with anhydrous ace-
tone (2 X 500 ml) and dried at 0.05 Torr to obtain 10.78 g (92.70%), melting point 140–145 C
(dec) of a yellowish powder corresponding to the AmB analogueA21. m/z [M + H]+ for
C54H82N4O18 calcd: 1075.5702, found: 1075.5719;A21 analogue HPLC spectrum is shown in
Fig 5. It was obtained with a model 600EWaters chromatograph coupled to a Waters 486
UV-Vis detector.
Electrophysiology
Single channel studies of the membrane pore of AmB and several of its derivatives were per-
formed using the tip-dip technique.
Preparation of small unilamellar vesicle. Cholesterol or ergosterol solutions were mixed
with POPC to obtain the desiredmol fraction of sterol (30%). The solvent was evaporated and
the suspension was prepared by adding the working solution (2 M KCl, 1 mMol CaCl2, 10
mMol HEPES [pH 8.0]) to the film deposited in the flask and then treated in an ultrasonic bath
to produce dispersion and obtain unilamellar vesicles [34]. The suspension was stored for 2 h
under refrigeration (4–6 C) prior to polyene incorporation.
Fig 4. 13C NMR spectrum of A21 analogue.
doi:10.1371/journal.pone.0162171.g004
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Polyene Incorporation. Powdered polyenes were stored at -20 C and used without further
purification. Stock solution (5 mMol) was prepared in DMSO and used the same day. In order
to homogenize, the sample in the solvent was subjected to ultrasonic dispersion. The proper
amount of the stock solution of the polyene was added to the small unilamellar vesicle (SUV)
preparation in order to obtain the desired concentration. Homogenized suspension was
obtained via ultrasonic dispersion in an N2 -enriched atmosphere after adding the polyene.
The antibiotic-liposomemicro emulsion was then immersed in an ultrasonic bath for 15 min
and stored at 4 C for 24 h before use in an N2 enriched atmosphere.
Micropipette Fabrication. Glass capillaries with filament were pulled using the P2000
instrument from Sutter Instruments (Novato, CA). Micropipettes were then filledwith the
same working solution used for the preparation of SUV’s and used within the following 20
min. The average resistance of micropipettes in the working solution was 100 ± 25 MΩ.
Solvent-Free Tip-Dip Lipid Bilayer Formation and ElectricalMeasurements. A sample
of the SUV was put in a controlled-temperature chamber, where the oxygen excess was
Fig 5. HPLC Chromatogram of A21 analogue.
doi:10.1371/journal.pone.0162171.g005
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removed by a continuous nitrogen flux. The sample was settled for 10 min at the desired tem-
perature, and then a bilayer was formed at the tip of the micropipette by consecutive immer-
sion in SUV suspension until a capacitive response to the square potential applied was
observed [35,36]. In all cases, the lipid concentration was 4 mg/ml. The standard seals obtained
in this manner were of ~100 GΩ with a 2 kHz low pass filter and a current root mean-square
Irms ~ 0.25 pA. The chamber was electrically insulated with a Faraday cage and suspended in
elastic bands to reduce the mechanical vibration. The current signal was amplified with an
Axopatch 200B and digitally converted with a Digidata 1320, both fromMDS Analytical Tech-
nologies (Toronto, Canada), and stored in a personal computer. The signal was acquired with
the aid of Clampex 8.2 software fromMDS Analytical Technologies at a frequency of 10 kHz.
The potential applied in all experiments was 100 mV. Care had to be taken to ensure that
experiments were being done in conditions of equilibrium.We determined the time average
conductance as a function of time and noticed that this property needs 15 min to attain equilib-
rium. All records were baseline-correcteda posteriori using an in-house computer program.
The currents here presented correspond to the average currents occurring in a 5 min experi-
ment obtained from an all points histogram. All graphics were done with XmGrace free
software.
UV Spectrophotometry
Dimerization of the L-Histidine derivative and AmB was determined using the absorption
spectra. UV Absorption Spectra for AmB and compoundA21 were obtained in the following
manner. Aliquots of the polyene (stock solution in DMSO for AmB and in PBS for A21, both
in N2 atmosphere were kept in closed vessels) were added to Dubelcco’s PBS solution at
pH = 7.46 at different concentrations and used to obtain the absorption spectra in a Hitachi U-
5100 spectrophotometer at rt under N2 atmosphere.
Toxicological Activity
Toxicological activity of the different compounds was determined via in vitro antifungal assays,
hemolysis tests, cell cultures and viability, as well as preclinical tests in mice and histopatholog-
ical analysis.
Statisticalmethods. The data were represented as the mean ± SD. The data were statisti-
cally analyzed using the SPSS 10.0 software (SPSS Inc., Chicago, Ill., USA), the t-test, and
ANOVA. Differences were considered significant if the p-value was less than 0.05. For dissemi-
nated candidiasis, we analyzed the results by a two-tailed Fisher’s exact test.
In vitro antifungal assays. The antifungal activity of the AmB and its analogs was deter-
mined by a flow cytometrymethod as previously described in reference [37]. For testing, we
used two strains of Candida albicans (ATCC 10231 and 752) and Candida krusei (ATCC
6258). 1 x 106 CFU/ml were seeded in plates of 96 wells. The cells were treated with AmB and
its analogA21 at concentrations of 0.01, 0.1, 1, 10, 100 and 1000 μM; furthermore in a zoom-in
experiment we also performed a second set at concentrations of 0.1, 0.2, 0.4, 0.6, 0.8 1.0 and
10 μM; AmB was dissolved in 1% v/v DMSO and A21 in a PBS solution with pH 7.4. We did
control experiments with the DMSO at 1% v/v solution and found the following toxicities:
0.5% for Candida albicans (ATCC 10231), 0.6% for Candida albicans (ATCC 752) and 0.2%
for Candida krusei (ATCC 6258). These values were subtracted from the respective results.
Cells were incubated for 24 h at 37 C under aerobic conditions; and collected by centrifugation
at 10,000 × g for 10 min. Cells were washed once in phosphate buffer solution stained with
0.1mg/ml propidium iodide (PI), and incubated for 30 minutes at rt and protected from light.
Finally the samples were analyzed by flow cytometry (Becton-DickinsonCalibur Facsc, 480 nm
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argon laser CA, USA). The parameters and intrinsic fluorescence in the FL2 channel (fluores-
cent yellow/orange) for FUN and channel FL3 (red fluorescence filter, 630 nm) for PI were pur-
chased and registered on a logarithmic scale for a minimum of 7500 events. The quadrants
were defined using the fluorescence of control samples, so they include up of 5% of cells in the
upper right quadrant, and then used to analyze the remaining samples to quantify the percent-
age of cells showing altered fluorescence compared to drug-free controls.
Hemolysis tests. The bloodwas drawn from humans into an evacuated siliconized glass
tube and stirred to remove fibrinogen in the Blood Bank of Instituto Nacional de Cancerología,
México. The bloodwas diluted with an isotonic phosphate buffer (PBS) solution with pH 7.4
and centrifuged at 2500 rpm for 15 min and the supernatant was discarded. The PBS consisted
of Na2HPO4 (7.95 g), KH2PO4 (0.76 g), NaCl (7.20 g), and distilledwater (1000 ml). The eryth-
rocytes were washed until supernatant was clear, and the packed cells were resuspended in PBS
buffer solution (pH 7.4) to form 2% red blood cells. The stock dispersion was stored in a refrig-
erator for a maximum of 48 h checking for stability by photometric monitoring. The hemolytic
activities of AmB and its analogs were investigated as describedby Jung et al., [38]. Briefly, 1 x
107 cells /ml were considered. Erythrocyteswere resuspendedwith 450 μl of a solution of 150
mMKCl + 3 mM Tris (pH 7.4). Erythrocyteswere treated with AmB and its analogs and were
incubated at 37 C for 1 h. Cells were treated with AmB and it analogA21 at concentrations of
0.01, 0.1, 1, 10, 100 and 1000 μM; (AmB was dissolved in 1% v/v DMSO andA21 in a PBS solu-
tion with pH 7.4). We did control experiments with a 1% v/v DMSO solution and found a tox-
icity of 28.13% for erythrocytes.This value was subtracted from all the results. Furthermore, in
a zoom-in experiment, we performed a second set at concentrations of 0.1, 0.2, 0.4, 0.6, 0.8 1.0
and 10 μM (AmB and A21 were prepared as mentioned above). After 24 h the solution was
centrifuged (Beckman Instruments Inc., USA) at 3000 rpm and the supernatants were taken
out. 100 μl of the supernatant was dissolved in 2 ml of an ethanol/HCl mixture to dissolve all
components and avoid the precipitation of hemoglobin. The supernatant was analyzed at 398
nm by UV spectrometer (UV-1601, Shimadzu, Japan). Normal saline concentration was used
as negative control (0% lysis) and distilledwater as positive control (100% lysis). The hemolysis
rate (HR) was calculated as follows:
HRð%Þ ¼ ððDs   DncÞ=ðDpc   DncÞÞ  100
where Ds, Dnc, and Dpc are the absorbance of the sample, the negative control and the positive
control, respectively. The experiments were run in triplicate and repeated twice.
Cell culture. Human renal cells (293Q cells) were obtained from the American Type Cul-
ture Collection (ATCC, No. CRL-1573). Cells were grown in Minimum Essential Medium
(MEM) with 5% FBS, 2 mM glutamine (GIBCO), 0.1 mM non-essential amino acids (GIBCO)
and 1 mM Sodiumpyruvate (GIBCO) at 5% CO2 and 37 C.
Cell viability. Cell viability and cell proliferation were determined using a MTT (methyl
tetrazolium, Sigma Aldrich, USA) assay [39]. Briefly, 293Q cells were seeded for cell viability
into a 96-well plate (10,000/well) and incubated for 24 h at 37 C and 5% CO2. The culture
mediumwas replaced by a fresh one supplemented with different concentrations of AmB and
its analogs and incubated for 24 h. Cells were treated with AmB and its analogs (A1 toA21) at
concentrations of 0.01, 0.1, 1, 10, 100 and 1000 μM (AmB and A1–A7 derivatives were dis-
solved in 1% v/v DMSO and A21 in a PBS solution with pH 7.4). We did control experiments
with the 1% v/v DMSO solution and found the toxicity to be 2.28% for kidney cells. This value
was subtracted from all the results. We also performed a second set at concentrations of 0.1,
0.2, 0.4, 0.6, 0.8 1.0 and 10 μM (AmB and A21 were prepared as mentioned above), in a zoom-
in experiment. After treatment (24 h) the mediumwas gently removed and replaced with 20 μl
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MTT (5 mg/ml) and 150 μl of non-phenol-redmedium, and incubated for 4 h. Medium from
each well was discarded, followed by the addition of 200 μl DMSO and 25 μl Sorensen’s glycine
buffer (glycine 0.1 M, NaCl 0.1 M, pH 10.5) to each well. When the formazan crystals were dis-
solved, the optical density was determined on a microplate reader (Bio-Rad) at a 590 nm wave-
length. Untreated cells served as non-treatment control cell viability. The results represented a
percentage of the relative viability of cells in comparison to the untreated control. MTT results
are presented as measurements relative to control values, expressed as percentages.
Animals. Male adult Balb-c mice (Harlan Laboratories Inc. Mexico) were used. The ani-
mals were housed in a temperature and humidity controlled environment and were allowed
food (Standard Purina Chow Diet, Mexico) and water ad libitum. All procedures were
approved by the Institutional Animal Care and Use Committee of the Veterinary Medical
School at the Universidad Nacional Autónoma deMéxico. Experiments were conducted fol-
lowing the rules and principles set in the Guide for the Care and Use of Laboratory Animals
(Ref: Revised guide for the care and use of laboratory animals. NIH guide. 1996; 25 [40]).
Disseminated candidiasis in adult mice:A C. albicans blastospore cell suspension of a cho-
sen strain at desired concentration in PBS was prepared. Inoculum concentrations were of 105
viable blastospores per mouse. C. albicans (ATCC 10–231) was obtained from ATCC and was
subcultured on Yeast-peptone-dextrose (YPD), agar/broth was used for growing the strain 24
h prior to infection. The inoculumwas prepared by placing three to five colonies in 5 ml of
sterile 0.15 M NaCl warmed to 35 C. Fungal counts of the inoculum, determined by viable
counts on SDA, were 6 ± 0.2 log10 CFU/ml. Disseminated infectionwas produced by injecting
the inoculumvia the dorsal tail vein using a 1ml tuberculin syringe and a 27-G, 1/2-in. needle.
Standard injection volumes ranged from 100 to 200 μl. Infected animal were followed for a
period of 21 days. Mice were observeddaily for disease symptoms. These included weight loss,
increased/decreasedmovement, abnormal posture (e.g., hunched back), and trembling. After
this period, animals were treated with the antifungal treatments.
Pharmacologicaltreatments and sample collection:Mice were randomly distributed into
the following groups of n = 6:
1. Control mice received 0.3 ml of PBS by IP, three times per week
2. Candidiasis
3. Candidiasis + AmB (DMSO), 4 mg/kg IP, every day per 15 days
4. Candidiasis + AmB (Abelcet1), 4 mg/kg IP, every day per 15 days
5. Candidiasis + A21, 4 mg/kg IP, every day per 15 days
6. Candidiasis + A21, 12 mg/kg IP, every day per 15 days
Drugs were administered via IP in a single dose and no more than 300 μl. AmB (DMSO)
was prepared in a 1% v/v DMSO solution. The maximum tolerated dose of DMSO for mouse is
2.5 mg/kg/day [41], hence the amount of DMSO applied is innocuous. Abelcet1 was prepared
with water for injectionUSP and A21 was dissolved in a PBS solution with pH 7.4.
Organ harvest and fungal burden determination:The kidneys, lungs, intestine, liver and
blood of each mouse were immediately removed and were placed in sterile 0.15 M NaCl at 4 C.
The organs were homogenized and were serially diluted 1:10. Aliquots were plated onto YPD
for viable fungal colony counts after incubation for at 35 C for 24 and 48 hr. The lower limit of
detectionwas 100 CFU/g of tissue. The number of colonies were counted and calculated and
the results were expressed as CFU/g of tissue. Six mice were used to compute average and stan-
dard deviations. Tissue fragments were fixed in 4% formaldehyde solution, dissolved in
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phosphate-saline buffer (pH 7.4), dehydrated in alcohol, and embedded in paraffin. Four-
micrometer paraffin sections were stained with hematoxylin and eosin (H&E) and subjected to
histopathological examination.
Acute toxicity: Two hundred and sixty Balb-Cmice were used and divided randomly into
treatment groups of 10 animals each (five females and five males). Animals were obtained
from random breeding in a closed colony. The control group received the vehicle (0.3 ml
sodium deoxicholate/phosphate saline buffer [pH 7.4]). The use of deoxicholate/phosphate
was in order to check the toxicity of the normal clinical formulation of AmB and since the
LD50 is 36 mg/kg [42] we expected to be innocuous as it was found. Five others groups were
treated with AmB (DMSO), at concentrations of 22, 25, 28, 30 and 35 mg/kg. Ten other groups
were treated with lipid complex AmB (Abelcet1) at concentrations of 22, 25, 28, 30, 35, 40, 50,
100, 200 and 300 mg/kg, and ten others withA21 at 22, 25, 28, 30, 35, 40, 50, 100, 200 and 300
mg/kg. AmB (DMSO), lipid complex AmB and A21 were administered via IP in a single dose
to mice once they had fasted for 18 h. AmB was prepared with 1% v/v DMSO, Abelcet1 was
prepared with water for injectionUSP and A21 was dissolved in a PBS solution with pH 7.4.
Mortality and clinical signs (general appearance, posture/body position, consciousness/atti-
tude, behavior, breathing, and salivation/vomiting) were recorded at 0.5, 1, 2, 4, 8, 12 h and 24
h after injection. Those animals that died during the observation period, as well as rodents that
survived to the end of the observation period,were autopsied. The concentrations in which
50%mortality (LD50) occurredwere obtained graphically by probit analysis, plotting concen-
tration against mouse mortality [43]. After 24 h, all data were summarized in tabular form,
showing for each test group the number of animals used, the number of animals displaying
signs of toxicity and the number of animals found dead during the test, time of death of indi-
vidual animals, a description and the time course of toxic effects and reversibility, and necropsy
findings. 51 animals died in the course of these experiments and the determined cause of death
was nephrotoxicity and hepatotoxicity.
Animal sacrifice:All animals that survived after study were killed for humane reasons and
200 mg/ml sodium pentobarbitone at a dosage of 200 mg/kg was used.
Histopathological analysis:Tissue fragments of treated and control animals were fixed in
10% formaldehyde solution, dissolved in phosphate-saline buffer (pH 7.4), dehydrated in alco-
hol and embedded in paraffin. Four-micrometer paraffin sections were stained with hematoxy-
lin and eosin (H&E) and subjected to histopathological examination.
Molecular Dynamics
We performedMolecular Dynamics studies of the AmB and the L-Histidine derivative of AmB
in aqueous solutions using the GROMOS 53A6 set of parameters [44] and ~7000 SPC water
molecules. In order to study the drug dimerization process we implemented the umbrella sam-
pling technique [45].
All MD simulations were performedwith Gromacs 4.5 [46] at 1 atm and 300 K. Both the
temperature and pressure were maintained close to their target values using the Berendsen
[47] weak coupling algorithm. A twin-range cut-off (0.8–1.4 nm) was used for the non-
bonded interactions. Interactions within the short-range cutoff were evaluated every time step
(2 fs), whereas interactions within the long-range cutoff were evaluated every 10 steps together
with the pair-list. To correct for the truncation of electrostatic interactions beyond the long-
range cutoff, the Reaction-Field correction [48] was applied (ε = 78). Bond lengths were con-
strained using the LINCS [49] algorithm for AmB and A21, and the SETTLE [50] algorithm
for the water. After energyminimization a 50 ps simulation was performedwith position
restraints applied on all heavy atoms of the AmB or A21molecules. The systems were then
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equilibrated for 5 ns without structural restraints. MD trajectory production and analysis was
performed after this point.
The relative orientation of each dimer pair was controlled by the use of six soft harmonic
potential restraints, technique known as the virtual bond algorithm [51]. This simplifies the
task of sampling a high number of degrees of freedom. The relative interaction strength of the
interfaces can be compared between all cases since the imposed restraints were included in the
unbiased procedure [52], which is a six-dimensional extension of the weighted histogram anal-
ysis method (WHAM) [53]. The comparison of the PMF profiles assumes that the relative ori-
entation of the two monomers does not matter at long distances, i. e., the system is insensitive
to the relative orientation of the monomers at the larger distances considered, typically when
the distance between the center of mass (COM) of each monomer is greater than 10 Å.
Potential of mean force (PMF). The PMF computation was obtained as a function of a
reaction coordinate, ξ, defined as the distance between the center of mass of the monomers.
The dimerization free energy is then computed as:
DG ¼   kBTlnK;









rðxÞ ¼ 2pxexpð  PMFðxÞ=kBTÞ;
Where kB is the Boltzman constant, T is the temperature, and ξ is the reaction coordinate. The
b subscript denotes the bound state, which includes only the first, most-pronouncedmini-
mum in the PMF profile, and u refers to the unbounded state. The prior concepts and meth-
odologywere used by Neumann et al. [54] for calculating the extent of the antibiotic
dimerization. The sampling of the reaction coordinate was done by dividing the studied inter-
val (4–25 Å) into equally sized windows, applying biasing forces on the six parameters used
by the VBA method to describe the system in order to overcome free energy barriers. For each
of these windows, 50 ns independent simulations were generated, sufficiently longer than the
characteristic time of the drugs internal dynamic processes, which may affect the dimerization
equilibrium. The starting structure for each windowwas obtained by a steeredMD simulation,
in which the drugmolecules forming a dimer in a particular conformation were pulled away
from each other with a constant velocity, up to the final dissociated distance. All systems in
each window were allowed to relax, with the distance betweenmonomers harmonically
restrained. The errors were obtained using a bootstrap procedure in which the trajectories
were cut in blocks of one fourth of the total length. 25 bootstraps ensembles were generated to
calculate the average and errors.
Expecteddrug dimerization. For a moderately large number of molecules, at low concen-





Where K was defined in the description of the PMF computation, Ni is the number of
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molecules of species i, v is the total volume of the system and v0 is a standard volume of nor-
malization (1.66 nm3), (see Ref [55]).
Molecularmodels of AmB and A21. The models we use are based on the GROMOS
53A6 set of parameters [42,56,57]. The 53A6 set of parameters was developed to include
parameterization of partitioning free energy data, in particular solvation of molecular building
blocks in water and alkanes, respectively. In comparison to earlier GROMOS force fields,
changes are especially found in non-bonded parameters, both Lennard-Jones parameters and
partial charges. Aromatic groups are described in more detail; instead of a united atom force
field for aromatic groups, the H-atoms on aromatic rings are described explicitly to account
more realistically for the charge distribution. The ester group is part of the standard building
blocks in 53A6 [44]. Parameters for the functional groups are derived by fitting to experimental
data for small molecules representative of the functional group, e.g. ethanol, propanol, and
butanol for the alcohol moieties. GROMOS87 uses the density and heat of vaporization of
small molecules for parameterization of non-bonded interactions. These are the popular Len-
nard-Jones 6–12 potential (LJ), and the electrostatic potential using Coulomb’s law. Both
potentials are used with a cut-off: pair interactions at distances larger than 1.4 nm are ignored.
For the LJ interaction, straight cut-off is used; the potential discontinuously drops to zero at
the cut-off. The Coulomb interaction is modified by the so-called reaction field scheme due to
Tironi et al. [58], which models screening of the charge-charge interactions due to a surround-
ing medium and in practice modifies the electrostatic interaction so that it smoothly goes to
zero at the cut-off. Parameters for bonded interactions, bond stretching, angle bending and tor-
sional motions are largely taken from spectroscopic (X-ray) data.
Atom types and their corresponding charges for AmB and A21molecularmodels are
shown in Table 2. Based on values defined for a specific atom type in the GROMOS 53A6 force
field, partial charges were slightly modified in order to account for the corresponding chemical
environment (2% in average, 14% in the worst case), and to balance each charged chemical
group in the molecule (zero net charge). The AmBmolecule, and similarly theA21molecule,
was thought to consisting of: a sugar molecule substituted with an ammonium group, which
we will call the “head”, linked to a macrocycle containing part of a sugar-like moiety substituted
by a carboxylate ion, a polyol, an ester, and a polyene, which we will call the “tail”, with the
same molecular characteristics. The choices for parameters for the alkyl backbone (alanine,
valine, etc.), polyols (analogous to serine and tyrosine), ammoniummoiety (lysine), and car-
boxylate moiety (glutamic and aspartic acid) are straightforward. Sugars required somemodifi-
cations to the standard alkyl and alcohol parameters in conjunction with the ring geometry.
Parameters consistent with GROMOS87 are described in a number of publications. We chose
those employed in a study of simple glycolipids (glucose with a single alkyl tail) as describedby
van Buuren et al. [59], which would be appropriate for the study of AmB and A21 interaction
with lipid bilayers. GROMOS87 also describes some co- factors for proteins: the polyene moi-
ety was modeled analogous to the building block retinol. This leaves the ester moiety as the
only non-standard building block in AmB. Breaking this group in pieces, the C = O group
mostly resembles the C = O group in the amide backbone building block. For the ester O and
connectedmethylene, we chose the same atom types as the ether O and connectedCH1 atoms
in sugars. Bond, angle parameters and charges were then taken from what in our view is the
best available set compatible with GROMOS87; the parameters used by to Chiu et al. [60] for
phospholipids.
Virtual bond algorithm (VBA): Description of the protocol used to compute the potential
of mean force and the details of the VBA as biasing potential are given in [61]. In short, three
anchors on each antibiotic molecule allowed for the definition of the relative orientation of the
two monomers. Anchors are definedwith the help of one distance, d, two angles, θ1 and θ2,
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Table 2. Force field definition for AmB and A21 atoms. Values for atom type, atom name, partial charge,
and mass are shown. In the case of A21, charges of the R chemical group were taken from the ARGN [44] or
HISA [57] 53A6 GROMOS residues. Atom name labels are mapped to the corresponding structure, shown in
Fig 6.
AmB
nr type atom charge mass
1 OA O15 -642 15.9994
2 H HAA 410 1.0080
3 CH1 C38 232 13.0190
4 CH1 C39 127 13.0190
5 NL N1 129 14.0067
6 H HAK 248 1.0080
7 H HAL 248 1.0080
8 H HAJ 248 1.0080
9 CH1 C40 232 13.0190
10 OA O16 -642 15.9994
11 H HAZ 410 1.0080
12 CH1 C41 210 13.0190
13 CH3 C42 0 15.0350
14 OA O17 -420 15.9994
15 CH1 C37 525 13.0190
16 OA O14 -525 15.9994
17 CH1 C11 210 13.0190
18 CH2 C10 0 14.0270
19 CR1 C13 0 13.0190
20 CR1 C14 0 13.0190
21 CR1 C15 0 13.0190
22 CR1 C16 0 13.0190
23 CR1 C17 0 13.0190
24 CR1 C18 0 13.0190
25 CR1 C19 0 13.0190
26 CR1 C20 0 13.0190
27 CR1 C21 0 13.0190
28 CR1 C22 0 13.0190
29 CR1 C24 0 13.0190
30 CR1 C25 0 13.0190
31 CR1 C26 0 13.0190
32 CR1 C27 0 13.0190
33 CH1 C28 0 13.0190
34 CH3 C35 0 15.0350
35 CH1 C29 232 13.0190
36 OA O11 -642 15.9994
37 H HAB 410 1.0080
38 CH1 C30 0 13.0190
39 CH3 C33 0 15.0350
40 CH1 C31 160 13.0190
41 CH3 C32 0 15.0350
42 OE O4 -360 15.9994
43 C C1 580 12.0110
44 O O9 -380 15.9994
(Continued )
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Table 2. (Continued)
45 CH2 C12 0 14.0270
46 CH1 C23 232 13.0190
47 OA O10 -642 15.9994
48 H HAC 410 1.0080
49 CH2 C34 0 14.0270
50 CH1 C45 232 13.0190
51 OA O19 -642 15.9994
52 H HAD 410 1.0080
53 CH2 C58 0 14.0270
54 CH2 C59 0 14.0270
55 CH1 C60 232 13.0190
56 OA O21 -642 15.9994
57 H HAE 410 1.0080
58 CH1 C61 232 13.0190
59 OA O22 -642 15.9994
60 H HAF 410 1.0080
61 CH2 C2 0 14.0270
62 CH1 C3 232 13.0190
63 OA O5 -642 15.9994
64 H HAG 410 1.0080
65 CH2 C4 0 14.0270
66 CH0 C5 337 12.0110
67 OA O6 -642 15.9994
68 H HAH 410 1.0080
69 CH2 C6 0 14.0270
70 OA O7 -315 15.9994
71 CH1 C9 210 13.0190
72 CH1 C8 0 12.0110
73 C C36 270 12.0110
74 OM O12 -635 15.9994
75 OM O13 -635 15.9994
76 CH1 C7 232 13.0190
77 OA O8 -642 15.9994
78 H HAI 410 1.0080
A21
nr type atom charge mass
1 NZ N1 -0.8800 14.0067
2 H HAA 0.4100 1.0080
3 OA O15 -0.6420 15.9994
4 CH1 C38 0.2320 13.0190
5 CH2 C39 0.0000 14.0270
6 CH1 C40 0.2320 13.0190
7 OA O16 -0.6420 15.9994
8 H HAI 0.4100 1.0080
9 CH1 C41 0.2100 13.0190
10 CH3 C42 0.0000 15.0350
11 OA O17 -0.4200 15.9994
12 CH1 C37 0.5250 13.0190
(Continued )
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Table 2. (Continued)
13 OA O14 -0.5250 15.9994
14 CH1 C11 0.2100 13.0190
15 CH2 C10 0.0000 14.0270
16 CR1 C13 0.0000 13.0190
17 CR1 C14 0.0000 13.0190
18 CR1 C15 0.0000 13.0190
19 CR1 C16 0.0000 13.0190
20 CR1 C17 0.0000 13.0190
21 CR1 C18 0.0000 13.0190
22 CR1 C19 0.0000 13.0190
23 CR1 C20 0.0000 13.0190
24 CR1 C21 0.0000 13.0190
25 CR1 C22 0.0000 13.0190
26 CR1 C24 0.0000 13.0190
27 CR1 C25 0.0000 13.0190
28 CR1 C26 0.0000 13.0190
29 CR1 C27 0.0000 13.0190
30 CH1 C28 0.0000 13.0190
31 CH3 C35 0.0000 15.0350
32 CH1 C29 0.2320 13.0190
33 OA O11 -0.6420 15.9994
34 H HAB 0.4100 1.0080
35 CH1 C30 0.0000 13.0190
36 CH3 C33 0.0000 15.0350
37 CH1 C31 0.1600 13.0190
38 CH3 C32 0.0000 15.0350
39 OE O4 -0.3600 15.9994
40 C C1 0.5800 12.0110
41 O O9 -0.3800 15.9994
42 CH2 C12 0.0000 14.0270
43 CH1 C23 0.2320 13.0190
44 OA O10 -0.6420 15.9994
45 H HAC 0.4100 1.0080
46 CH2 C34 0.0000 14.0270
47 CH1 C45 0.2320 13.0190
48 OA O20 -0.6420 15.9994
49 H HAD 0.4100 1.0080
50 CH2 C58 0.0000 14.0270
51 CH2 C59 0.0000 14.0270
52 CH1 C60 0.2320 13.0190
53 OA O21 -0.6420 15.9994
54 H HAE 0.4100 1.0080
55 CH1 C61 0.2320 13.0190
56 OA O22 -0.6420 15.9994
57 H HAF 0.4100 1.0080
58 CH2 C2 0.0000 14.0270
59 CH1 C3 0.2320 13.0190
60 OA O5 -0.6420 15.9994
(Continued )
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Table 2. (Continued)
61 H HAG 0.4100 1.0080
62 CH2 C4 0.0000 14.0270
63 H HAH 0.4100 1.0080
64 OA O6 -0.6420 15.9994
65 H HAM 0.4100 1.0080
66 OA O8 -0.6420 15.9994
67 CH1 C7 0.2320 13.0190
68 CH2 C6 0.0000 14.0270
69 CH0 C5 0.3370 12.0110
70 OA O7 -0.3150 15.9994
71 CH1 C9 0.2100 13.0190
72 CH1 C8 0.0000 13.0190
73 C C36 0.4500 12.0110
74 OM O12 -0.4500 15.9994
75 H HAK 0.4400 1.0080
76 H HAL 0.4400 1.0080
77 N N2 -0.3100 14.0067
78 H HAN 0.3100 1.0080
79 CH3 C62 0.1600 15.0350
80 OM O18 -0.3600 15.9994
81 O O19 -0.3800 15.9994
82 C C63 0.5800 12.0110
83 CH1 C64 0.0000 13.0190
84 CH2 C65 0.0000 14.0270
85 C C66 0.0000 12.0110
86 H HAP 0.3100 1.0080
87 NR N3 -0.0500 14.0067
88 C C67 0.1400 13.0190
89 NR N4 -0.5400 14.0067
90 C C68 0.1400 13.0190
doi:10.1371/journal.pone.0162171.t002
Fig 6. Molecular structure of AmB and A21, showing atom names according to definitions in Table 2.
doi:10.1371/journal.pone.0162171.g006
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and three dihedral angles, φ1, φ2, and φ3. These restraints where added to the topology of the
system as harmonic restraints for distances and dihedral angles and a cosine angle potential for




Substitutions in polyenes have been performed for a long time in the search for improved selec-
tivity (see for example [62–65]). Here, amide substitutions were used to synthesize AmB ana-
logues. AnaloguesA1 toA7 were synthesized from aliphatic and aromatic amines in order to
increase steric and electronic effects between the amide moiety and the micosamine ring. Thus,
benzyl amide was selected for preparation of A1 in order to induce a steric effect between the
aromatic ring and the mycosamine unit of the molecule. In addition, aromatic rings could
favor the π-π interaction between the rings of adjacent molecules in the pore supra-structure.
H-π interactions between the OH group of the micosamine and aromatic rings of A1 could
lead to steric effects affecting pore formation. Cyclohexyl amine and diisopropyl amine were
selected for the synthesis of A2 and A3 with the purpose of comparing moderate and strong
steric factors. In addition to the π-π and H-π interactions described for A1, A4 and A5 have
the effect of a chiral carbon on the amide moiety. A6 and A7 were designedwith the purpose
of having analogues displaying UV fluorescence, to facilitate visualization on the formation of
channels, while the additional presence of the heterocyclic idole ring, the methylene group and
the ester functionality would lead to larger steric effects.A6 and A7 showed a better perfor-
mance in the selectivity of fungal vs mammal cells. We thought that the presence of nitrogen
groups could be partially responsible for this. We thus decided to consider a derivative with
increased number of nitrogen atoms in the ring. Although histamine substitution was thought
of as a possibility, we found that such a derivative reverted to the parent molecule in tissue cul-
ture tests. Therefore, we ended up with a derivative having the imidazol ring and the methyl
ester to prevent hydrolysis, that is,A21. Post-purification yields, representative Infrared signals
and High ResolutionMass Spectrometryof several examples are shown in Table 1.
Electrophysiological experiments
These analogs were tested for transmembrane transport in POPC/cholesterol lipid bilayers, by
means of the tip dip technique, in order to determine their ability to produce K+ leakage.
Table 4 shows the open probability, i.e., the percentage time that a channel appears conducting
Table 3. Virtual bond algorithm parameters used to define and control the relative orientation of the monomers for the three dimers conforma-
tions studied in this work. Angle values are given in degrees. A, B, C refer to the atom index of monomer one, and a, b, c refer to the atom index of mono-
mer two. These sets of atoms define the anchor VBA angles used as bias potentials during the PMF calculations, with force constants kd, kθ and kφ (as in Ref
[59]).
HTA HHA HHP
[˚] A B C a b c [˚] A B C a b c [˚] A B C a b c
θ1 96 30 18 120 96 30 18 149 90 30 18 108
θ2 96 30 120 108 96 59 120 108 90 18 120 108
φ1 0 30 18 120 108 9 30 18 108 120 0 30 18 108 120
φ2 -76 59 18 30 108 -96 59 18 30 120 -90 59 18 30 120
φ3 70 149 108 120 18 -96 149 108 120 30 90 149 108 120 30
kd = 2500 kJ mol-1 nm-2 kθ = 500 kJ mol-1 kφ = 250 kJ mol-1 rad-2
doi:10.1371/journal.pone.0162171.t003
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current through the K+ conducting pores. It must be noted that the concentration used for all
derivatives is 200 μM, whereas it is only 10 μM for AmB. This is due to the reduced formation
of pores shown by most of the derivatives.
Furthermore all compounds, except for A3 and A21, exhibit the first five channel types,
with the larger conductance channel (~ 70 pS) appearing in half the compounds. Of course, the
different concentrations required for channel expression could lead to different aggregation of
the compounds in an aqueous solution: either the derivatives require a large concentration to
aggregate or larger aggregates are needed for insertion of the derivatives into the membrane.
However, the fact that the smallest conductance channel (~ 4 pS) is by far the most frequent
also indicates that the expression of the derivatives’ channels is also hindered.
Pharmacological experiments
Reduced activity in cholesterol-containing membranes could perhaps be reflected in increased
selectivity. Hence, the derivatives were tested in pharmacological studies, of fungal cells, eryth-
rocytes and kidney cells; the results are presented in Table 5. The pharmacological results agree
with the electrophysiological experiments: there is very poor toxicity toward mammalian cells.







Hemolysis in human red
blood cells
Cytotoxic activity on kidney cells
ATCC CRL-1573
IC50[μM] IC50[μM] IC50[μM] HeC50 [μM] TC50 [μM]
AmB 1 0.20 >10 7 9.7
A1 >100 >100 >100 52 100
A2 >100 >50 >100 45 120
A3 >100 >50 >100 53 180
A4 >100 >50 >100 46 80
A5 >100 >50 >100 42 100
A6 >100 >50 >100 58 120
A7 8.2 1.5 >10 80 220
A21 0.67 0.28 7.5 409 >500
doi:10.1371/journal.pone.0162171.t005
Table 4. Probability of opening of the different types of channels observed for: AmB and the compounds presented in Table 1 in a lecithin mem-
brane with 30% Mol cholesterol.
Open probability
[] μM 200 200 200 200 200 200 200 200 10
Type a A1 A2 A3 A4 A5 A6 A7 A21 AmB b
I 2% 5% < 1% 7% 10% 23% 14% n.o. 0.59%
II 1% < 1% n.o. 3% 2% 2% 7% 13.7% 0.26%
III < 1% < 1% n.o. 1% < 1% < 1% < 1% n.o. 0.08%
IV < 1% < 1% n.o. < 1% < 1% < 1% < 1% n.o. 4.06%
V < 1% < 1% n.o. < 1% < 1% < 1% < 1% n.o. 1.81%
VI < 1% < 1% n.o. < 1% < 1% n.o. n.o. n.o. 0.93%
a Ref [12]
b Ref [14]
n.o. = not observed
doi:10.1371/journal.pone.0162171.t004
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Given that there is also poor toxicity towards fungal cells in most of the derivatives, no major
advantage could be obtained, except in the cases of A7 and A21.
In the case of A7 there is a reduction in toxicity that is larger for the mammalian cells than
the fungal ones, leading to an increase in selectivity, albeit a reduced one. These results and the
idea of promoting interaction with the membrane led to using (L)-histamine as a substitute,
which produced a derivative with increased selectivity. Nonetheless, this amide reverted to
AmB action on kidney cells after 24 h, probably due to the action of proteases. In order to pre-
vent this possible hydrolytic pathway, we screened a series of AmB amide analogues containing
nitrogen heterocyclic ring systems where the (L)-histidinemethyl esther 21 led to the analogue
known as A21. This produced the best results.
As may be seen in Table 5, the performance of this derivative exhibits a considerable
increase in selectivity. This derivate is presented in Fig 2.
Electrophysiological experiments
We took a more detail look at the derivative’s electrophysiology and found that it exhibits a
pattern for total average conductance (the average conductance when all types of channels are
considered) in ergosterol- and cholesterol- containing membranes, with much increased selec-
tivity. These results are presented in Table 6, where they are compared to those of AmB. Selec-






Where Gergosterol refers to the conductance in ergosterol-containingmembrane, Gcholesterol
refers to the conductance in cholesterol-containing membrane, [polyene]cholesterol refers to the
corresponding concentration of the polyene in the cholesterol-containing membrane and
[polyene]ergosterol refers to the corresponding concentration of the polyene in the ergosterol-
containing membrane. The increment in selectivity (4.33 fold) of compoundA21 is in agree-
ment with the pharmacological results presented in Table 5.
Furthermore, the single channel experiments allowed us to compare the transmembrane
pores formed by AmB and A21 that enable the passage of K+. Figs 7 and 8 show the corre-
sponding single channel currents for AmB and theA21 derivate; smaller channels (type I) are
common for AmB and A21 in cholesterol-containing POPCmembranes. In ergosterol-con-
taining POPCmembranes,A21 presents a channel of 6 pS as the most common one, similar to
type IV of Ref [13].
Spectroscopic experiments
An additional advantage of theA21 derivate is its increased solubility in water;A21 readily dis-
solves at 50 mMol, whereas AmB does so only in the μMol range. Also, the dimerization of
Table 6. Average total conductance produced by AmB and derivative A21 in POPC membranes with 30% Mol cholesterol or ergosterol; selectiv-
ity is described in the text.





AmB 15 23 ± 15 - - - 3.5 1
5 - - - 48 ± 11
A21 200 108 ± 11 - - - 15.16 4.33
10 - - - 712 ± 33
doi:10.1371/journal.pone.0162171.t006
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both components seems to occur at different concentrations in aqueous solution. The profile of
UV Absorbance of AmB has been observed to be different in its monomeric or aggregated
form [66]. An estimate of polyene aggregation can be obtained from the ratio between the
Absorbance at a wave length of 409 nm and the corresponding one at a wave length of 347 nm.
When plotted as a function of the concentration, it is possible to determine the threshold for
the onset of dimerization. The first wave length is characteristic of a monomeric state of the
polyene, whereas aggregation produces absorbance at the second wave length [56,66]. Care
should be taken to determine these spectra in inert atmosphere since it has been shown that
oxidation of AmB gives rise to bands in the same region that the band used for determining
dimerization [67]. The spectra corresponding to theA21 derivative at different concentrations
are presented in Fig 9, as well as the corresponding spectra of AmB. As may be seen the range
of concentrations at which the profiles change are quite distinct. Fig 9 also shows the profile of
Fig 8. Example of single channel along 1 s activity of A21 in a POPC membrane containing 30% Mol ergosterol or
30% Mol cholesterol, 25˚C, 100 mV and concentrations of 10 and 200 μMol, respectively. A larger channel for the
ergosterol-containing membrane is presented (note the different scale) since, in this case, it is very common. These records
were treated as described in the Methods section.
doi:10.1371/journal.pone.0162171.g008
Fig 7. Example of single channel along 1 s activity of Amphotericin B in a POPC membrane containing 30% Mol
ergosterol or 30% Mol cholesterol, 25˚C, 100 mV and concentrations of 5 and 15 μMol respectively. These records were
treated as described in the Methods section.
doi:10.1371/journal.pone.0162171.g007
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the rate of Absorbance at 347 nm / Absorbance at 409 nm of derivativeA21 and AmB. This
ratio is constant at first, reflecting the presence of a single profile. At certain concentration, the
rate starts to increase as aggregation begins to appear. A bilinear adjustment to this profile
shows a dimerization onset for A21 at 8 μMol whereas this onset for AmB occurs at 0.2 μMol.
The latter is smaller than the previously reported dimerization at 1 μg/ml [66], that is ~ 1
μMol, probably due to the effect of avoiding oxidation. The increased solubility of A21 yields
an advantage in the therapeutic use of the derivative, and its increased selectivity could be a
result of the difference in the onset of dimerization. See the Methods section for the details of
the Absorbance experiments.
Molecular dynamics
We also looked into the molecular basis of the increased selectivity of A21 from a theoretical
standpoint, using a molecularmodeling and a thermodynamics approach. Aggregation is one
of the proposedmolecular factors responsible for the mechanism behind of AmB selectivity.
Given the previous results and following this hypothesis, we carried out a comparative study of
the dimeric aggregation of AmB vs that of A21 in an aqueous solution. Long-time-scale
Fig 9. Top figures: Absorption spectra in a PBS solution at 30 C of different concentrations of the polyenes. The left hand side presents
AmB spectra at concentrations of 0.15, 0.3, 0.6, 0.9, 1.2 and 1.5 μMol, corresponding to a small- to- large profile. The right hand side
presents A21 spectra at concentrations of 2, 8, 14, 20, 26, and 32 μMol, corresponding to a small- to large- profile. Bottom figures: Ratio
between absorbance at 409 nm and that at 347 nm as a function of concentration. Left hand side, AmB; and right hand side, A21.
doi:10.1371/journal.pone.0162171.g009
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simulations were performed on two equivalent systems. We placed two molecules of either
AmB or A21 in a water solution having 150 mMNaCl, a temperature of 27 C and a volume
large enough to have low concentrations of the drug. Fig 10 summarizes the results.
The dipole moment predicted by our force field yielded a value of 35 D for the AmBmole-
cule. In contrast, theA21molecule has an electrical dipole of 10 D. These values do not change
with the formation of a dimer since we do not include polarization effects.We speculate that
the significant difference in the dipole values could explain the molecular aggregation process.
Hence, different dimer configurations were considered in this work, namely, head-to-head
(HH) or head-to-tail (HT), with parallel (P) or anti-parallel (A) relative orientations of the
dipole moment. Schematic drawings of these arrangements are presented in Fig 10A. The
molecular dynamics simulations showed stable configurations of the HTA, HHP and HHA
dimers. However, the HTP configuration disassembledwithin a couple of nanoseconds and
eventually reassembled in the HTA configuration. This effect happened for both AmB and
A21HTP dimers.We decided to exclude the HTP configuration from further analysis due to
its very unstable behavior.
To characterize the fact that the self-association thermodynamic process of the drug
depends on the relative dimer orientation, we computed the potential of mean force (PMF),
reported for AmB and A21 in Fig 10B. This strategy has already been used successfully, e. g., to
study protein-protein interactions inside a membrane. Details of this methodology are pro-
vided in [61] and in the Methods section.Moreover, to quantify the energetic cost involved in
the monomer−monomer interactions, we calculated the dimerization free energy, ΔG, from
the PMF profiles. The ΔG values for a standard state imposed by the simulation conditions are
shown in Table 7. As expected, the most favorable dimerization energies correspond to a con-
figuration with antiparallel dipoles. This result applies to both AmB and A21 in the HTA ori-
entation, which presents the lowest local minimum in the PMF profiles. Furthermore, AmB
has an energy advantage of ~ 4 kcal/mol in comparison toA21. The free energy difference
means that the AmBHTA dimers are more stable in an aqueous solution than theA21 coun-
terpart. In other words, A21 solubility in water is greater than AmB.
It must be mentioned that the ΔG value of the HHP configuration of AmB is found between
the two antiparallel configurations.We can explain this particular behavior by considering the
amphiphilic nature of the molecule. Reports indicate that the AmBmolecule has a high ten-
dency to undergo lipophilic interactions with other AmBmonomers in aqueous media [57].
Starzyk et al. [56] made the first calculation to quantify the total electrostatic and van derWaals
contributions to the AmB-dimerization energy when two molecules are parallel or anti-parallel
to each other in an aqueous solution. Despite a robust analysis, however, they did not take the
dipole moment of the molecule into account. The authors suggested a hydrophobic nature of
the dimerization process because the AmB polar groups are involved in the interaction with
water molecules rather than stabilizing contacts in the dimer. In the parallel orientation, the
AmB-AmB stability comes from strong van derWaals interactions due to a large contact sur-
face. On the other hand, in the antiparallel geometry, the AmB dimer is stabilizedmostly by the
electrostatic interaction between the hydroxyl chains and the hydroxyl tail group. Hence, the
energy advantage of the HHP over the HHA configuration in the AmB dimer arises from the
fact that the hydrophobic effect is stronger than the electrostatic and van derWaals-type inter-
actions. Nevertheless, the predominant energy contribution for dimerization is the one resulting
from dipole-dipole interaction.We found that antiparallel dipole configurations exhibited a
greater stability in all cases. Therefore, we propose that the selectivity difference between the
two drugs originated in the smaller dipole moment of A21 relative to AmB.
We additionally estimated the extent of dimerization as a function of drug concentration
using the predicted equilibrium constant, K, derived from the PMF profiles. The results are
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Fig 10. Thermodynamic molecular characterization of drug dimer formation. A) Schematic representation of the three
conformations of dimers studied. From the top, head-to-tail with anti-parallel dipole moment (HTA), head-to-head with anti-parallel
dipole moment (HHA), and head-to-head with parallel dipole moment (HHP). B) Potential of mean force (PMF) as a function of reaction
coordinate ξ in the HTA (black), HHA (red) or HHP (blue) configurations, for AmB (top) and A21 (bottom). Estimated error shown with
dashed lines. C) Expected drug dimerization as a function of molar concentration, for AmB (solid lines) and A21 (dashed lines) on HTA
(black), HHA (red) or HHP (blue) configurations. D) Molecular dimer structure in equilibrium in the HTA configurations for AmB (top)
and A21 (bottom). Inkscape, xmgrace and VMD were used to make panels A, B and C, respectively.
doi:10.1371/journal.pone.0162171.g010
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shown in Fig 10C. Also, analysis of the equilibratedmolecular structure of the HTA conforma-
tion suggests that A21 weakens dimers because the interaction between the polyene rings is
perturbedby the presence of the L-Histidine group that replaces the AmB carboxyl group (Fig
10D). Overall, the predicted relative behavior betweenAmB and A21 in the dimerization pro-
cess shows good agreement between theory and experiment. Following Huang et al. [31], we
believe there is a need of dimerization for the appearance of ion channels in cholesterol-con-
taining membranes. In order to examine this, we looked into the pharmacological effects of
both compounds as a function of concentration.
Pharmacological experiments
The potency of the AmB and A21 compounds against Candida albicans strains at different
concentrations is shown in Fig 11. A very similar behavior is observed for both compounds,
indicating that the antimycotic character of the parent molecule is preserved. Furthermore,
A21 presents larger toxicity in the case of Candida krusei, which is AmB resistant. There is a
very similar trend of action of both compounds as a function of concentration of up to
10 μMol; pore expression in the ergosterol-containingmembrane is therefore similar.
Fig 12 shows a comparison of the effects that AmB and A21 have on hemolysis at different
concentrations, as well as on renal cells (293Q).A21 has a considerably reduced hemolytic
effect, which agrees with the observations of the single channel pores in cholesterol-containing
membranes. The same may be seen in the case of kidney cells: at 100 μMol AmB there is almost
total reduction of viability, whereas 100 μMol A21 produces only a 10% decrease. AmB in cho-
lesterol-containing membranes showed the effect of drug dimerization at 1 μMol and starts to
affect RBC and kidney cells. On the other hand, A21 starts dimerization around 8 μM. In Fig
12 we can observe that AmB at 1 μM has the same effect on mammal cells that A21 at 100 μM,
a difference of two orders of magnitude, close to the MD predicted difference in the dimeriza-
tion onset of the compounds. On the other hand, the spectroscopic prediction on the dimeriza-
tion onsets ratio for both compounds is closer to the observed ratio of the drug’s lethal toxicity,
see Table 8.
A crucial test regarding the improved safety and equivalent efficacy of theA21 derivative
needs to involve preclinical tests in mammals. This was done using groups of Balb-Cmice
(n = 10). After intraperitoneal (IP) injection of the compounds, most mice in the 100 to 300
mg/kg AmB groups were quiet and inactive and died approximately 12 h after the injection.
The majority of mice in the 40 to 300 mg/kg AmB treatment died within 24 h following the
injection. In contrast, no mice died after a treatment with 40–300 mg/kg of A21 after 12 h,
whereas most mice treated with 200 and 300 mg/kgA21 died within 24 h following the injec-
tion. The corresponding LD50 obtained were 29.3 mg/kg for AmB and 199.48 mg/kg for A21;
that is, almost a 7-fold increase in regards to AmB. This is shown in Table 8, where a compari-
son that includes Abelcet1, is presented.
Table 7. Free energy of dimerization of AmB and A21 in an aqueous solution in three possible con-
figurations (HTA, HHA, HHP). The distance between the center of mass (COM) of the polyene ring of the
monomers for the geometry of minimal energy is also given.
AmB A21
dm [Å] ΔG [kcal/mol] dm [Å] ΔG [kcal/mol]
HTA 5.9 -11.9 6.6 -8.1
HHA 7.1 -1.6 6.1 -5.1
HHP 5.1 -2.1 5.8 -0.9
doi:10.1371/journal.pone.0162171.t007
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Kidney histological analysis stresses the observeddifference in toxicity. Animals treated
with 28 mg/kg AmB for 24 h exhibited clusters of dilated degenerative tubules, containing exfo-
liated necrotic epithelium and necrotic tubules, but no histological changes were observed in
kidney slices from animals treated with 28 mg/kg of A21. However, animals treated with 200
mg/kgA21 for 24 h showed very tight and congested glomeruli, as well as convoluted tubules
with isquemic damage as shown in Fig 13, which agrees with this being the lethal dose.
In order to verify the efficacy of theA21 compound on a candidiasis infection, produced by
Candida albicans (ATCC 10231), two forms of AmB, a soluble one (DMSO) and a lipid
Fig 11. Comparative action of Amphotericin B and derivative A21 on Candida albicans ATCC 10231 (A), Candida
albicans ATCC 752 (B) and Candida krusei ATCC 6258 (C). Cells were incubated for 24 h at 37 C under aerobic
conditions, stained with propidium iodide (PI). Antifungal activity was determined by flow cytometry. The results are
presented as means ± SD of 3 independent experiments. *p < 0.05 is the comparison with control value. #p< 0.05 the
comparison with AmB.
doi:10.1371/journal.pone.0162171.g011
Fig 12. A) Comparative effect in hemolysis of human RBCs by AmB and A21 after 2 h incubation at 37 C (data represented as
mean ± SD; n = 8). Significant differences with respect to control or AmB are indicated with *p < 0.05 and #p < 0.05, respectively. B)
Changes in the survival of kidney cells HEK-293Q after treatment with different concentrations of AmB (DMSO) and A21 during a 24
h incubation period (control = 100%). The results are presented as means ± SD of 3 independent experiments. *p < 0.05 is the
comparison against control value. #p < 0.05 the comparison against AmB.
doi:10.1371/journal.pone.0162171.g012
An Amphotericin B Derivative Equally Potent to Amphotericin B and with Increased Safety
PLOS ONE | DOI:10.1371/journal.pone.0162171 September 28, 2016 29 / 38
complex one (Abelcet1), were compared toA21. Balb-c mice were infected and allowed to
incubate for three weeks. At the end of this period, different mice groups were treated for
another two weeks with the different compounds. For the three compounds, an IP dose of 4
mg/kg/day was used. This dose is higher than the therapeutic IV dose of 1 mg/kg/day. The rea-
son for using this dose is that 5–20 mg/kg/day of AmB have been used previously when admin-
istered intraperitoneally [27]. We also considered 12 mg/kg/day for A21, since the augmented
safety could allow a dose increase if needed.We used the 4mg/kg dose of Albecet because we
found it to be as effective as the solution formulation of AmB, and we wanted to determine its
toxicity at this dose vs those of AmB and A21 at the same value that was previously used for IP
application [27]. The results are summarized in Tables 9 and 10.
Table 8. Comparison of the LD50 produced in Balb-C mice by Amphotericin B (in two presentations)
and A21 derivative.
Drug LD50
AmB (DMSO) 29.3 mg/kg
Abelcet1 > 80 mg/kg
A21 199.48 mg/kg
doi:10.1371/journal.pone.0162171.t008
Fig 13. Histopathological analysis of kidney samples from animals treated, with AmB (DMSO), AmB (Abelcet1) and A21.
(A) Appearance of normal renal tubules in a kidney from a representative uninfected male Balb-C mouse treated for 2 weeks with
daily IP doses of sodium deoxycolate (control). (B) Kidney from a representative male Balb-C mouse treated with a single IP dose of
28 mg/kg AmB (DMSO), showing clusters of dilated degenerative tubules (d) containing exfoliated necrotic epithelium admixed with
necrotic tubules (n). (C) Kidney from a representative male Balb-C mouse treated with a single IP dose of 80 mg/kg AmB
(Abelcet1). (D) Kidney from a representative Balb-C mouse treated with a single IP dose of 28 mg/kg A21 where a lesser amount of
necrotic and degenerative tissue is observed. Rare tubules lined by regenerative epithelium with intraluminal protein casts are
visible. (E) Kidney from a representative Balb-C mouse treated with a single IP dose of 200 mg/kg A21, showing clusters of dilated
degenerative tubules (d) containing exfoliated necrotic epithelium, admixed with necrotic tubules (n), as well as inflammatory cells
(ic). G = glomerulus; IP = intraperitoneal; PT = proximal tubule; TD = distal tubule; H&E-stained magnification 100X.
doi:10.1371/journal.pone.0162171.g013
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Table 10 shows that all compounds alleviate the infection in a similar manner, with a slight
advantage observed in the case of Abelcet1 and A21. Increasing the dose of A21 did not
remove the minimal intestinal damage that appeared with the 4 mg/kg dose. The microbiolog-
ical studies of intestine, blood, kidney, and lung of infected and treated mice, show a strong
infection of all organs in infectedmice, whereas the organs of those treated with the two forms
of AmB and the two doses of A21 present only traces of Candida. In short,A21 performs as
effectively as AmB.
Histological sections of the organs show, as previously observed, that A21 caused less dam-
age to the cells that AmB in its two presentations. Figs 14 and 15 show histological sections of
the intestines and kidneys of control and treated animals.
Conclusions
We have presented a multidisciplinary approach that advances the understanding of polyene
action. Nonetheless, there are some limitations involved.
Table 10. CFU from C. albicans recovered from intestine, liver, kidney and lung homogenates of infected mice treated with AmB and A21.
Candidiasis Intestine*20 ± 3 Liver*30 ± 5 Kidney*18 ± 4 Lung*9 ± 3
AmB (DMSO) (4 mg/kg) 6 ± 2a 5 ± 1a 4 ± 1a 3 ± 0.5a
AmB Abelcet1 (4 mg/kg) 4 ± 1a 6 ± 1a 2 ± 0.3a 3 ± 0.1a
A21 (4 mg/kg) 10 ± 3a 6 ± 2a 2 ± 0.2ab 4 ± 1a
A21 (12 mg/kg) 6 ± 1.5ac 3 ± 0.5abc 3 ± 0.1ac 2 ± 0.2abc
* Log10 CFU/g of tissue.
a p< 0.05 as compared with candidiasis group.
b p< 0.05 as compared with AmB DMSO.
c p< 0.05 as compared with AmB Abelcet1.
A two-tailed Fisher’s exact test was used.
doi:10.1371/journal.pone.0162171.t010
Table 9. Histopathological evaluation of infected mice treated with AmB or A21.




Number of mice with histiocytic,
neutrophilic,
multifocalbronchopneumonia in lungs
vs. mice in treatment group.




lysis vs. mice in treatment
group.
Number of mice with liver
necrosis and
degeneration and
cholestatic liver vs. mice
in treatment group.
Candidiasis 6/6 6/6 6/6 6/6
AmB (DMSO)
(4 mg/kg)




0/6a 1/6ab 0/6ab 1/6ab
A21 (4 mg/
kg)
0/6ab 0/6abc 1/6ab 0/6ab
A21 (12 mg/
kg)
0/6ab 0/6abc 1/6ab 0/6ab
a p < 0.05 as compared with Candidiasis group;
b p < 0.05 as compared with AmB (DMSO);
c p < 0.05 as compared wih AmB (Abelcet1);
A two-tailed Fisher’s exact test was used.
doi:10.1371/journal.pone.0162171.t009
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The synthesis of derivatives was made starting from an AmB compound, which is not 100%
pure in as much as it also contains Amphotericin A and Amphotericin C, leading to the deriva-
tives inheriting this impurity. However, its purity (91.78%) is similar to that of the Sigma
Amphotericin B, United States Pharmacopeia (USP), Reference Standard (88.91%) as tested by
HPLC. Although AmB is usually prescribed by the intravenous route, antimycotics were
applied to mice intraperitoneally. As a result of this, some values may be different, such as the
LD50, but the relative efficacy and toxicity between both compounds should be reliable. As pre-
viously mentioned, Molecular Dynamics results are very dependent on the force fields used,
and since we had to construct the necessary force fields, they have not been extensively tested.
As a matter of fact, comparison of the electrostatic description of the AmBmolecule produce
by this force field with that provided by an ab-initio calculation [68] shows discrepancy even in
the predicted dipole moment. Nonetheless, we can expect relative comparisons between the
two polyenes to be more reliable. This is supported by the agreement shown with the experi-
mental predictions on relative dimerization. The electrophysiological comparison between
Amphotericin and its derivatives was performed in very simple systems, membranes patches of
Fig 14. Histopathological analysis of intestinal epithelium obtained five weeks after Candida albicans inoculation in mice.
(A) Intestinal epithelium of Balb-C mouse with normal appearance. (B) Intestinal epithelium showing severe damage with necrotic
enteritis. We can observe the loss of microvilli (■), presence of inflammatory cells (ic) and cellular lysis (*) is observed. (C) Intestinal
epithelium from a representative mouse with candidiasis treated with a daily IP dose of 4 mg/kg AmB (DMSO) during the last two of
the five weeks. Loss of microvilli (■), presence of inflammatory cells (ic), and cellular lysis (*) is observed. (D) Intestinal epithelium
from a representative mouse with candidiasis treated with a daily IP dose of 4 mg/kg AmB (Abelcet1) during the last two of the five
weeks. The kidney appears normal and has abundant caliciform cells. (E) Intestinal epithelium from a representative mouse with
candidiasis treated with a daily IP dose of 4 mg/kg A21 during the last two of the five weeks. Epithelium with normal appearance. (F)
Intestinal epithelium from a representative mouse with candidiasis treated with a daily IP dose of 12 mg/kg A21 during the last two of
the five weeks. Epithelium with normal appearance.
doi:10.1371/journal.pone.0162171.g014
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POPC containing ergosterol or cholesterol in order to mimic the difference between fungal and
mammal cells. The validity of the model was supported by subsequent results in microbiology
and animal experiments. Thus, the multidisciplinary character of the research gives more con-
fidence regarding the obtained results.
Our findings are based on the idea that membrane structure is behind polyene selectivity
and results showed that nitrogenated amides with a reduced dimerization lead to an increase in
selectivity and, therefore, to reduced collateral toxicity. We advance this hypothesis based on
the proposedmechanism of action derived from channel formation, which is affected by self-
association of the polyene in the aqueous solution, as proposed by Huang [31] and Starzyk
[56]. We were not able to structure an explanation of the increase selectivity of derivativeA21
based on the sponge model. Our derivative modifies a region opposed to the proposed region
of interaction of the polyene with the sterol in this latter model. Moreover, difference in aggre-
gation of polyenes does not seem to play a role in this model.
Table 11 shows a summary of the distinct effects of AmB and derivateA21 on fungal and
mammalian cells, as well as a comparison with two other recent AmB derivatives with
increased selectivity that have appeared in the literature. The increase in selectivity produced
Fig 15. Histopathological analysis of kidney obtained five weeks after Candida albicans inoculation in mice. (A)
Kidney of Balb-C mouse with normal appearance. (B) The kidney shows severe pyelonephritis with fungal infiltration (●). The
image shows clusters of dilated degenerative tubules (d) containing exfoliated necrotic epithelium admixed with necrotic
tubules (n). The inflammatory infiltration (ic) damaged the lining of the tubules. Renal tubular nephrosis was observed. (C)
Kidney from a representative mouse with candidiasis treated with a daily IP dose of 4 mg/kg AmB (DMSO) during the last two of
the five weeks. Clusters of dilated degenerative tubules (d) containing exfoliated necrotic epithelium admixed with necrotic (n)
and apoptotic tubules (a) appear. (D) Kidney from a representative mouse with candidiasis treated with a daily IP dose of 4 mg/
kg AmB (Abelcet1) during the last two of the five weeks, with normal appearance. (E) Kidney from a representative mouse with
candidiasis treated with a daily IP dose of 4 mg/kg A21 during the last two of the five weeks. The kidney shows normal
appearance. (F) Kidney from a representative mouse with candidiasis treated with a daily IP dose of 12 mg/kg A21 during the
last two of the five weeks, showing a normal appearance.
doi:10.1371/journal.pone.0162171.g015
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by all new derivatives is clear, as is the advantage of compoundA21, encouraging its possible
therapeutic use.
We have introduced a novel AmB derivative with considerably increased safety in the treat-
ment of mycosis (almost 7-fold via IP), and equal efficacy. A considerable advantage of the
increased solubility of A21 is that it can be delivered in aqueous or PBS solution. Moreover,
even the highest dose applied in the acute toxicity study could be delivered just in aqueous
solution. This could result in a better antibiotic for medical use in the treatment of fungal infec-
tions that are a growing health risk [69] and in the treatment of other ailments for which AmB
has been proposed, e.g. protozoa and neoplastic cells.
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